System C, a UK-based provider of healthcare and local government technology solutions, has announced the strategic acquisition of CIS Oncology, a UK-based supplier of chemotherapy prescribing and management systems.
The acquisition marks a significant expansion of System C's offerings in medicines management as CIS Oncology is most known for its chemotherapy prescription and management system, ChemoCare.
ChemoCare has been widely adopted by NHS trusts as the chemotherapy care solution accelerates and streamlines prescribing and patient management through accessible technology, providing enhanced convenience and reliability for NHS trusts.
The company is set to launch ChemoPRO, an innovative app that will empower patients by providing instant access to their medical information and enabling seamless communication with healthcare professionals, early next year.
the acquisition of the oncology technology company complements System C's existing portfolio of EPR, maternity and neonatal, prescribing, and pharmacy solutions
CIS Oncology's comprehensive cancer informatics solutions streamline data management, enables precision medicine approaches, and facilitate coordinated care, empowering patients with personalised treatment plans and supporting multidisciplinary cancer teams in making well-informed decisions.
Further, the acquisition of the oncology technology company complements System C's existing portfolio of EPR, maternity and neonatal, prescribing, and pharmacy solutions. Once integrated, System C customers will be able to manage the entire prescription journey with a single unified experience through which clinicians and oncologists can prescribe chemotherapy and non-chemotherapy drugs.
CEO of System C, Nick Wilson, said: "We are delighted to welcome CIS Oncology to the System C family. This acquisition shows our commitment to delivering seamless care, prioritising patient and clinical safety, and forging stronger connections with our customers as they embrace digital solutions across health and social care.
"By integrating CIS Oncology's expertise, we are now even better equipped to provide high-quality and cost-effective ePrescribing solutions that not only meet our customers needs but reinforce our dedication to the NHS and our UK-centric approach. We’re looking forward to working together with CIS Oncology to leverage our collective expertise to significantly transform healthcare and shape the future of patient care."
The acquisition marks a significant expansion of System C's offerings in medicines management as CIS Oncology is most known for its chemotherapy prescription and management system, ChemoCare
CEO at CIS Oncology, Tony Pegg, said; "CIS Oncology Ltd has always been about working with our customers to improve patient outcomes in the safest and most efficient way possible. Joining forces with System C will strengthen that position across a broader offering to the NHS. We look forward to working together to continue helping the NHS and healthcare providers through further digitisation and, ultimately, ever-improving patient outcomes."
The acquisition also reflects System C's proactive approach to exploring how automating medicines management can lead to improved patient safety while easing the burden on the NHS, a development that is vital in the current healthcare climate. System C are already actively engaged with the Automating 4 Better Care (A4BC) forum, chaired by Lord Carter, to define the priorities for medicines interoperability to feed into national funding prioritisation.
Earlier this year System C announced the launch of its new look electronic patient record (EPR) solution, CareFlow EPR, a fully integrated patient record solution that combines patient administration, clinical operations, maternity and neonatal capability, pharmacy, and prescribing.